Annovis Bio, Inc.
NYSE:ANVSBiotechnology
+$0.00 today
- Market cap
- $51.64M
- Beta
- 1.24
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.47
Volume 1.35M
Average 1.08M
Returns on capital
Annovis Bio, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-171.2%
avg 14.0%
ROIC
-170.2%
avg -63.7%
ROA
-136.9%
avg -301.4%
Analysis
ROA is currently the strongest return metric at -136.9% versus its period average of -301.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Maria L. Maccecchini | Founder, Acting CFO, CEO, President & Executive Director | USD 808K | 75 | — | — |
Hilda Maibach | Senior Vice President of Statistics | — | — | — | — |
Cheng Fang | Chief Scientific Officer | — | — | — | — |
Blake Jensen | Head of Quality | — | — | — | — |
Eve Damiano | Senior Vice President of Regulatory Operations | — | — | — | — |
Compensation is shown in the reported currency; data updated Sep 26, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
16
$2.23M
Sells
0
$0.00
Net Transaction Value
+$2.23M
Net buying
Most Active
Hoffman Michael B
16 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| May 20, 26May 20, 2026 | Hoffman Michael B Direct | Buy | $104.4K$104,367.21 |
| May 20, 26May 20, 2026 | Hoffman Michael B Direct | Buy | $33.9K$33,928.20 |
| May 20, 26May 20, 2026 | Hoffman Michael B Direct | Buy | $4.5K$4,483.50 |
| Apr 2, 26Apr 2, 2026 | Hoffman Michael B Direct | Buy | $1.5M$1,498,980.00 |
| Dec 8, 25Dec 8, 2025 | Hoffman Michael B Direct | Buy | $63.6K$63,600.00 |
| Dec 8, 25Dec 8, 2025 | Hoffman Michael B Direct | Buy | $130.2K$130,194.00 |
| Nov 24, 25Nov 24, 2025 | Hoffman Michael B Direct | Buy | $116.6K$116,598.40 |
| Nov 24, 25Nov 24, 2025 | Hoffman Michael B Direct | Buy | $1.7K$1,718.10 |
| Nov 24, 25Nov 24, 2025 | Hoffman Michael B Direct | Buy | $35.4K$35,420.00 |
| Nov 24, 25Nov 24, 2025 | Hoffman Michael B Direct | Buy | $6.1K$6,149.57 |
1–10 of 16
Summary
Insiders reported 16 buys worth $2.23M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $2.23M. Hoffman Michael B was the most active insider with 16 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Competitors
Who does Annovis Bio, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about ANVS's management, answered from reported figures.
Who manages ANVS?
Annovis Bio, Inc. (ANVS) lists 5 active executives. The top listed executive is Hilda Maibach, Senior Vice President of Statistics.
Are ANVS insiders buying or selling?
Recent insider activity shows net buying of $35.39M.
Continue the stock analysis
Jump to another research area for this company.